The report by Tsirka et al. (1) provided a very useful update of the outcomes for infants and children who develop dilated cardiomyopathy (DCM). Their use of a category combining death and cardiac transplant (“heart death”) as end points was sensible and helpful. However, some of the diagnostic categories were less than fully explained and somewhat arbitrary. If patients with muscular dystrophy (n = 4) and inherited metabolic disorders (n = 5), both uniformly fatal diseases, were not included, their total population of DCM would be only 82 instead of 91, and the population of survivors with recovery of normal contractility would amount to 40% of that population. This raises a serious question about proceeding to transplantation in the first year of the disease, as four centers have advised on the basis of their perception that DCM had such a poor prognosis. In this published cohort, some recovered as late as six years after onset; would 40% of the transplanted children have recovered with normal contractility had they not been transplanted?